What factors affect cosentyx dosing in obese patients?

How do obese patients respond to standard Cosentyx dosing?

Standard Cosentyx regimens for plaque psoriasis and psoriatic arthritis give 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks. [1]
Obese patients show modestly lower exposure to secukinumab compared with non-obese patients, but clinical response rates remain comparable when the labeled dose is used. [2]

When does weight-based dosing become relevant?

Weight-based adjustments are not required or recommended in the Cosentyx prescribing information. [1] The manufacturer states that population pharmacokinetic analyses found body weight has only a minimal effect on secukinumab pharmacokinetics. [2]
No clinical trials have tested a dedicated weight-based regimen for patients whose body mass index exceeds 30.

What happens if obese patients receive a higher dose?

Higher doses such as 300 mg every two weeks have been studied in psoriasis trials that included heavier patients. [2]
Higher-frequency dosing raised exposure levels proportionally, but side-effect rates did not increase significantly. [3]
Some clinicians increase frequency to every two weeks after week 4 for patients who show partial response at month 3, regardless of weight.

Why are companies challenging this patent?

Secukinumab is protected by multiple patents listed on DrugPatentWatch.com, including composition-of-matter coverage until at least 2031. [4]
Companies have filed paragraph IV certifications challenging these patents, paragraph IV filings indicating intent to launch generic versions once the earliest patents expire. [4]
Link: https://www.drugpatentwatch.com/drug/Cosentyx

How do biosimilars affect future dosing decisions?

Biosimilars to secukinumab will likely arrive after patent expiry,届时会带来价格 reductions that may erleichtern access to higher-frequency regimens for obese patients who need them.